Guardant Health Reports Strong 2025 Revenue Growth, Secures $287M Legal Win, and Advances Key Product Approvals

summarizeSummary

Guardant Health's 2025 annual report reveals strong revenue growth, a substantial $287 million legal win against Natera, and favorable patent dispute outcomes, alongside key regulatory approvals and expanded coverage for its cancer screening and diagnostic tests.

check_boxKey Events

• Strong 2025 Financial Performance

  Total revenue increased 33% to $982.0 million for the year ended December 31, 2025, with net loss decreasing to $416.3 million from $436.4 million in 2024, and net cash used in operating activities improving to $184.8 million from $239.9 million.

• Major Legal Victory Against Natera

  A jury unanimously found in favor of Guardant Health in a false advertising lawsuit against Natera, Inc., awarding the company $287.0 million in damages, including punitive damages, which was affirmed by the court in July 2025.

• Favorable Patent Dispute Outcomes

  The USPTO issued an office action rejecting all claims of a key patent ('631) in the TwinStrand Biosciences infringement suit, and a court granted Guardant Health's motion to dismiss Tempus AI's patent infringement claims with prejudice in January 2026.

• Expanded Product Regulatory Approvals and Coverage

  The Shield blood test received FDA approval, Medicare coverage, and inclusion in National Comprehensive Cancer Network guidelines, while Guardant Reveal and Guardant360 Tissue tests also saw expanded Medicare coverage.

auto_awesomeAnalysis

Guardant Health's annual report details robust financial performance in 2025, with significant revenue growth and improved cash burn. The company achieved a major legal victory, being awarded $287 million in a false advertising lawsuit against Natera, and secured favorable outcomes in patent disputes against TwinStrand Biosciences and Tempus AI, which could significantly reduce potential liabilities and strengthen its intellectual property. These legal developments, combined with critical regulatory approvals and expanded coverage for its Shield blood test and other oncology diagnostics, underscore strong market adoption and future growth potential. The acquisition of MetaSight Diagnostics further enhances its technology portfolio, providing a solid foundation for continued innovation and commercial expansion in precision oncology.